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ABSTRACT
OBJECTIVE: To investigate the HCV cascade of care and to identify the factors associated 
with loss or absence  to follow-up of patients identified as infected with hepatitis C through 
blood donation.
METHODS: Blood donors from 1994 to 2012, identified with positive anti- HCV by enzyme 
immunoassay and immunoblot tests were invited to participate in the study, through letters or 
phone calls. Patients who agreed to participate were interviewed and their blood samples were 
collected for further testing. The following variables were investigated: demographic data, data 
on comorbidities and history concerning monitoring of hepatitis C. Multiple regression analysis 
by Poisson regression model was used to investigate the factors associated with non-referral for 
consultation or loss of follow-up.
RESULTS: Of the 2,952 HCV-infected blood donors, 22.8% agreed to participate: 394 (58.2%) 
male, median age 48 years old and 364 (53.8%) Caucasian. Of the 676 participants, 39.7% did 
not receive proper follow-up or treatment after diagnosis: 45 patients referred not to be aware 
they were infected, 61 did not seek medical attention and 163 started a follow-up program, but 
were non-adherent. The main reasons for inadequate follow-up were not understanding the 
need for medical care (71%) and health care access difficulties (14%). The variables showing a 
significant association with inadequate follow-up after multiple regression analysis were male 
gender (PR = 1.40; 95%CI 1.15–1.71), age under or equal to 50 years (PR = 1.36; 95%CI 1.12–1.65) 
and non-Caucasians (PR = 1.53; 95%CI 1.27–1.84). 
CONCLUSIONS: About 40.0% of patients did not receive appropriate follow-up. These data 
reinforce the need to establish strong links between primary care and reference centers and the 
need to improve access to specialists and treatments. 
DESCRIPTORS: Blood Donors. Hepatitis C diagnosis. Lost to Follow-Up. Risk Factors. Cascade 
of Care. 
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INTRODUCTION
Hepatitis C virus (HCV) currently affects 180 million persons, approximately 3.0% of the 
world population26. HCV infection is a leading cause for liver transplantation and accounts 
for approximately 700,000 deaths annually25,a. Apart from cirrhosis, many HCV-infected 
patients suffer from mental and physical comorbidities, with reduced physical and social 
functioning4,12. HCV infection has also been associated with diseases such as insulin resistance 
and diabetes and may negatively affect other organ systems11,12.
Despite the availability of effective therapies for its treatment such as direct-acting agents, 
HCV infection remains underdiagnosed, and millions of patients worldwide living with HCV 
are unaware they are infected and thus not receiving care (e.g., education, counseling, and 
medical monitoring) or treatment14,22.
Several barriers to hepatitis C care and treatment have been previously identified14. These 
barriers may arise at the patient, health care service, physician, and government levels, 
Some of these identified obstacles include the lack of symptoms9, low perceived treatment 
need and the perception that HCV infection is incurable29, health care access difficulties13,20, 
adverse effects associated with interferon-α therapy20, concurrent intravenous drug use, 
alcohol abuse, and social stigma24,29.
Many studies reported that a significant percentage of patients with confirmed diagnosis do 
not receive adequate treatment and follow-up care5,13,17,24. In Brazil, little is known about the 
clinical follow-up and outcomes of HCV-infected persons. Understanding the characteristics 
of persons diagnosed with hepatitis C and those not referred to treatment can help target 
appropriate follow-up of these patients. 
The study aimed to investigate the HCV cascade of care and to identify the factors 
associated with loss or absence  to follow-up of patients identified as infected with hepatitis 
C through blood donation.
METHODS
From March 2012 to October 2013, we conducted a cross-sectional study among a cohort 
of retrospectively identified HCV infected blood donors. Participants were blood donors 
screened for HCV from 1994 to 2012 at Fundação Pró Sangue/Hemocentro de São Paulo 
(FPS), which is the largest blood center in Latin America, in São Paulo, Southeastern Brazil; 
it collects approximately 120,000 units of blood annually, and provides blood products to 
more than 100 hospitals in the greater metropolitan area of São Paulo.
HCV antibodies were screened using an enzyme-linked immunosorbent assay (ORTHO 
HCV 3.0, Biolab-Mérieux S/A, Rio de Janeiro, Brazil), and a recombinant immunoblot 
assay (CHIRON RIBA HCV 3.0 S/A, Chiron Corporation, Emeryville, USA) was used as a 
confirmatory test.
Participants reactive for both enzyme-linked immunosorbent assay and recombinant 
immunoblot assay tests were enrolled. All blood donors aged 18 to 67 at FPS from 1994 to 
2012 were eligible and this study included all HCV infected blood donors.
We invited reactive donors to participate in the study by letter, email, or telephone call. 
Patients who agreed to participate in the study went through an interview and we collected 
a new blood sample for additional laboratory tests and detection of HCV-RNA. 
HCV follow-up information after blood donation was collected using a questionnaire, 
laboratory test results, and a medical appointment.
The vital status of eligible donors who could not be located or enrolled in the study 
was determined using data from the national death index system2,b to detect missing 
a World Health Organization. 
Hepatitis C: fact sheet. Geneva; 
2016 [cited 2016 Febr]. Avaliable 
from: http://www.who.int/
mediacentre/factsheets/fs164/en/ 
b Ministry of Health (BR), 
Department of STD, AIDS, and 
Viral Hepatitis. SIM: Mortality 
Information System. Brasília (DF); 
[cited 20 Mar 2017]. Available 
from: http://www.aids.gov.br/en/
pagina/mortality-information-
system-sim
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patients. The record linkage was performed using the Record Linkage III, a probabilistic 
linkage software specially developed to associate records considering the Portuguese 
language phonetics. Studies use this method aiming at tracking blood donors from the 
FPS in the SIM6.
The hepatitis C cascade of care was assessed using the information collected in the 
questionnaire. We obtained the data to estimate the proportion of blood donors who have 
not received adequate clinical follow-up after diagnosis.
In this study, adequate clinical follow-up was defined as to be informed about serological 
status, referred for consultation, attended by specialist, and referred for drug therapy, 
if indicated.
According to the status of follow-up after diagnosis, two groups emerged, that is, those 
patients referred to follow-up for HCV infection (hereafter Referred group) and patients not 
referred to follow-up for HCV infection (Non-referred group).
To investigate the reasons for non-referral to appropriate treatment services for HCV 
infection, we compared several variables that may be associated with non-referral between 
the Referred and Non-referred groups. We analyzed the variables core demographic 
characteristics (gender, race, age, and education level); risk factors for HCV transmission 
(previous drug use and blood transfusion); comorbidities (such as hypertension, diabetes, 
psychiatric, rheumatic, and skin disorders); alcohol or active illegal drug use; and barriers 
to care (awareness of hepatitis C infection, access to laboratory tests and medical services, 
compliance to clinical follow-up, and drug therapy).
The real-time polymerase chain reaction (PCR) detected HCV-RNA using a commercially 
available kit (CobasAmpliPrep/CobasTaqMan HCV test, version 2.0; Roche Diagnostics, 
Branchburg, NJ, USA)13.
The qualitative variables were expressed as frequencies and percentages, and the 
quantitative variables, as measures of central tendency. A bivariate analysis investigated 
the factors associated with a lack of or loss to clinical follow-up. For the binary outcomes, 
the correlation between exposure and outcome was estimated using the prevalence ratio 
(PR). Variables with a p < 0.20 by univariate analysis were entered in a multiple analysis 
using a Poisson regression model with robust variance. Variables with a p < 0.05 in the 
multiple analysis were retained in the final model. Lastly, the PR of each such variable 
was estimated together with the corresponding confidence interval (95%CI) at the 5% 
significance level3,7,8.
The Ethics Committee for Research Project Analysis (CAPPesq) at Hospital das Clínicas, 
Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP), approved this study in 
December 2011 (Protocol 8583). All participants signed an informed consent form.
RESULTS
Of the 2,952 blood donors with HCV infection on the FPS database, 676 (22.8%) agreed to 
participate in the study (Figure 1). Most participants were male (58.2%), Caucasian (53.8%), 
and ≤ 50 years old (55.3%). The median age was 48 years old. 
The main route of HCV infection was prior blood transfusion (216 donors; 31.9%). In our 
study, 92 (13.6%) of respondents reported using intravenous illegal drugs and 73 (10.7%) 
reported using intranasal drugs.
To better characterize our sample, we compared the characteristics of the participant blood 
donors with those of the nonparticipant donors. The variables available for comparing were 
gender and year of donation. The participants were most males and individuals who donated 
blood between 2000 and 2012 (p < 0.001).
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Figure 2 shows the complete hepatitis C cascade of care. Almost 1/4 of the participants lost 
the follow-up and, consequently, did not receive adequate HCV care, despite having the HCV 
diagnosis confirmed after blood donation (Figure 2).
Of the 676 participants, 269 (39.7%) did not receive adequate follow-up after diagnosis: 
45 (16.7%) patients referred not to be aware they were infected, 61 (22.7%) were aware 
they were infected but did not seek medical attention and 163 (60.6%) patients started 
a follow-up program, but were non-adherent. Additionally, the main reasons for 
inadequate follow-up among these 269 patients were not understanding the need for 
medical care (71%) and health care access difficulties (14%). Other reasons included 
the patient’s own decision to interrupt treatment (3%) and other non-specified or 
unknown causes (12%).
The variables that showed a significant association with inadequate follow-up after 
univariate analysis were male gender, age under or equal to 50 years and non-Caucasian 
race (Table 1). After multiple regression analysis, the same variables showed association 
with inadequate follow-up: male gender, age under or equal to 50 years and non-Caucasian 
race (Table 2).
Figure 2. Hepatitis C cascade of care among 676 blood donors diagnosed with HCV infection at Fundação 
Pró Sangue/Hemocentro de São Paulo (FPS). São Paulo, SP, Southeastern Brazil, from 1994 to 2012.
676 (100%)
631 (93.3%) 610 (90.2%)
570 (84.3%)
321 (47.5%)
293 (43.4%)
133 (19.6%)
163 (24.1%)
0
100
200
300
400
500
600
700
800
Blood donors
anti-HCV+
Aware Referred for
consultation
Attended by
specialist
Referred for
therapy
Initiated
treatment
SVR Lost follow-up
Figure 1. Flowchart showing results of 2,952 blood donors with HCV infection on Fundação Pró 
Sangue/Hemocentro de São Paulo (FPS). São Paulo, SP, Southeastern Brazil, from 1994 to 2012.
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Table 2. Predictors of non-referral to HCV therapy according to multiple regression analysis among 
676 participants blood donors at Fundação Pró Sangue/Hemocentro de São Paulo (FPS). São Paulo, 
SP, Southeastern Brazil, from 1994 to 2012.
Variable PRnet PRadjusted 95%CI p
Gender 0.001
Female 1 1
Male 1.42 1.40 1.15–1.75
Age (years) 0.002
> 50 1 1
≤ 50 1.41 1.36 1.12–1.65
Caucasian < 0.001
Yes 1 1
No 1.56 1.53 1.27–1.84
Table 1. Predictors of non-referral to HCV therapy according to univariate analysis among 676 participants 
blood donors at Fundação Pró Sangue/Hemocentro de São Paulo (FPS). São Paulo, SP, Southeastern Brazil.
Variable Total
Inadequate treatment
PR 95%CI p
n %
Gender 0.001
Female 282 90 31.9 1.0
Male 394 179 45.4 1.42 1.16–1.74
Age (years) 0.001
> 50 302 98 32.5 1.0
≤ 50 374 171 45.7 1.41 1.16–1.72
Caucasian < 0.001
Yes 364 115 31.6 1.0
No 312 154 49.4 1.56
Education (years)a 0.072
≤ 12 511 212 41.5 1.0
> 12 146 48 32.9 0.79 0.61–1.02
Comorbidities 0.106
No 316 136 43.0 1.0
Yes 360 133 36.9 0.86 0.71–1.03
Frequent alcohol useb 0.352
No 191 71 37.2 1.0
Yes 474 195 41.4 1.11 0.89–1.37
Received blood transfusion 0.926
No 461 184 39.9 1.0
Yes 215 85 39.5 0.99 0.81–1.21
Relatives with hepatitis C 0.421
No 539 212 39.3 1.0
Yes 105 41 39.1 0.99 0.76–1.29
Does not know 32 16 50.0 1.27 0.88–1.83
Intravenous drug use 0.929
No 584 232 39.7 1.0
Yes 92 37 40.2 1.01 0.77–1.32
Intranasal drug use 0.084
No 532 203 38.2 1.0
Yes 144 66 45.8 1.20 0.98–1.48
Unknown data: a 19, b 11.
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DISCUSSION
In our study, 40% of blood donors diagnosed with HCV through blood donation did not 
receive adequate follow-up after diagnosis. The main reasons for loss to follow-up in this 
population were their lack of understanding about the need for clinical care and health care 
access difficulties. Moreover, the variables male gender, non-Caucasian race, and age equal 
or less than 50 years old were associated with inadequate follow-up.
Many studies have shown that a significant percentage of patients with confirmed diagnosis 
of hepatitis C do not receive adequate treatment and follow-up care, highlighting the need 
for strategies to improve the HCV cascade of care1,5,10,20,23,27.
In Europe18 and in the United States16, approximately 43% and 65%, respectively, of patients 
with hepatitis C receive specialized treatment17. However, the reasons for the lack of referral 
for HCV therapy vary across the studies. For instance, in the USA, the main barrier to care is 
the fact that most individuals with HCV ignore that they are infecteda. Conversely, in Europe, 
the lack of financial resources, illegal drug use, and alcohol abuse are the main barriers to 
care17. Moreover, the risk group most associated with a lack of or loss to follow-up includes 
individuals who inject illegal drugs1,5,16,17,29.
The main reasons for loss to follow-up among our cohort were the lack of understanding 
of patients about the need for clinical care (71%) and health care access difficulties (14%).
Sundus et al.23, investigated the causes for loss to follow-up of hepatitis patients at a liver 
center of a tertiary care hospital in Pakistan, a developing country, and found that 85% 
of patients did not adhere to follow-up for not understanding the importance of clinical 
follow-up, thus highlighting the importance of medical advice about this chronic infection 
and its implications so that patients receive the diagnosis and adhere to follow-up treatment.
Health care access difficulties have been extensively described as a significant barrier to 
HCV treatment, which requires a specialized medical team and specific laboratory and 
pharmaceutical structure10,16,20.
Age equal or less than 50 years old and low education level were also associated with an 
increased risk of inadequate clinical follow-up in our study. In fact, other studies have reported 
similar findings1,2,21,28.
In relation to the limitations in our study, the population was composed of blood donors, a cohort 
previously selected by clinical and epidemiological screening. Thus, our findings may not be 
representative of the general population. However, blood donors are an indirect source of health 
information of the general population. In addition, the data in our study are representative of only 
22.8% of all HCV-infected blood donors on the FPS database in the 1994-2012 period.
Furthermore, participant donors differ from non-participants regarding the distribution of 
gender and year of donation and may not be representative of the whole donors. In fact, most 
HCV+ blood donors identified during the study period were not located. Failure to respond 
to the contact invitation for the study may have been due to a lack of knowledge about the 
infection and its implications or a lack of interest in follow-up care. Therefore, the patients 
who participated in the study may represent the most conscious group about the perceived 
need for HCV treatment and follow-up. Conversely, patients who did not participate in the 
study may be less concerned and knowledgeable about the disease and its risks.
In Brazil, hepatitis C diagnosis generally occurs at a primary level, by the general practitioner 
or at blood banks. However, hepatitis C treatment is provided only by specialist services in 
secondary or tertiary services. An estimated 2-3 million persons have hepatitis C virus18. 
Nevertheless, less than 0.5% of this population has been treated.
From December 2015, new direct-acting medications have been introduced for the treatment 
of hepatitis C in Brazil, with high success rate and few side effects. Different studies show 
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that increasing levels of diagnosis and treatment, in combination with improved treatment 
efficacy, are critical strategies for achieving substantial reductions in disease burden15,26. 
In conclusion, about 40% of patients l did not receive appropriate follow-up after hepatitis 
C diagnosis. Additionally, this study identified significant barriers to care of HCV-infected 
blood donors after diagnosis, highlighting multiple opportunities for improvement along 
the hepatitis C cascade of care in Brazil. Our data reinforce the importance of a close link 
between blood centers and reference services and the need to improve access to specialists 
and treatments. Despite recent improvements in treatment, the real benefits will only be 
achieved with effective measures for dealing with barriers to care. Appropriate resource 
allocation and comprehensive public health policies are crucial to engage effectively 
individuals with chronic HCV in care and treatment.
REFERENCES
1. Astell-Burt T, Flowerdew R, Boyle P, Dillon J. Is travel-time to a specialist centre a risk factor 
for non-referral, non-attendance and loss to follow up among patients with hepatitis C (HCV) 
infection? Soc Sci Med. 2012;75(1):240-7. https://doi.org/10.1016/j.socscimed.2012.02.046.
2. Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators 
of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. 
Harm Reduct J. 2014;11:1. https://doi.org/10.1186/1477-7517-11-1.
3. Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an 
empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res 
Methodol. 2003;3:21. https://doi.org/10.1186/1471-2288-3-21.
4. Boscarino JA, Lu M, Moorman AC, Gordon SC, Rupp LB, Spradling PR, et al. Predictors of poor 
mental and physical health status among patients with chronic hepatitis C infection: The Chronic 
Hepatitis Cohort Study (CHeCS). Hepatology. 2015;61(3):802-11. https://doi.org/10.1002/hep.27422.
5. Bruggmann P. Accessing hepatitis C patients who are difficult to reach: it is time to overcome 
barriers. J Viral Hepat. 2012;19(12):829-35. https://doi.org/10.1111/jvh.12008.
6. Capuani L, Bierrenbach AL, Abreu F, Takecian PL, Ferreira JE, Sabino EC, et al. 
Accuracy of a probabilistic record-linkage methodology used to track blood donors in 
the Mortality Information System database. Cad Saude Publica. 2014;30(8):1623-32. 
https://doi.org/10.1590/0102-311x00024914.
7. Coutinho LMS, Scazufca M, Menezes PR. Métodos para estimar razão de 
prevalência em estudos de corte transversal. Rev Saude Publica. 2008;42(6):992-8. 
https://doi.org/10.1590/s0034-89102008000600003.
8. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ. 
1998;316(7136):989-91. https://doi.org/10.1136/bmj.316.7136.989.
9. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of 
hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National 
Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012;55(6):1652-61. 
https://doi.org/10.1002/hep.25556.
10. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. 
N Engl J Med. 2013;368(20):1859-61. https://doi.org/10.1056/nejmp1302973.
11. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic 
hepatitis C infection beyond the liver. Clin Gastroenterol Hepatol. 2010;8(12):1017-29. 
https://doi.org/10.1016/j.cgh.2010.08.026.
12. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the 
United States. Clin Infect Dis. 2012;55 Suppl 1:S3-9. https://doi.org/10.1093/cid/cis393.
13. Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, et al. The 
hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One. 
2014;9(5):e97317. https://doi.org/10.1371/journal.pone.0097317.
14. McGowan CE, Monis A, Bacon BR, Mallolas J, Gonçales FL, Goulis I, et al. A global view 
of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 
2013;57(4):1325-32. https://doi.org/10.1002/hep.26246.
8Hepatitis C among blood donors Machado SM et al.
https://doi.org/10.1590/S1518-8787.2017051006468
15. Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence-based interventions to 
enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum. Int J 
Drug Policy. 2015;26(10):922-35. https://doi.org/10.1016/j.drugpo.2015.05.002.
16. Mitruka K, Thornton K, Cusick S, Orme C, Moore A, Manch RA, et al. Expanding primary care 
capacity to treat hepatitis C virus infection through an evidence-based care model – Arizona and 
Utah, 2012-2014. MMWR Morb Mortal Wkly Rep. 2014;63(18):393-8.
17. Papatheodoridis GV, Tsochatzis E, Hardtke S, Wedemeyer H. Barriers to care and 
treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver Int. 
2014;34(10):1452-63. https://doi.org/10.1111/liv.12565.
18. Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MR, et al. 
Prevalence and risk factors of hepatitis C virus infection in Brazil, 2005 through 2009: 
a cross-sectional study. BMC Infect Dis. 2013;13:60. https://doi.org/10.1186/1471-2334-13-60.
19. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future 
disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral 
Hepat. 2014;21 Suppl 1:34-59. https://doi.org/10.1111/jvh.12248.
20. Searson G, Engelson ES, Carriero D, Kotler DP. Treatment of chronic hepatitis C virus 
infection in the United States: some remaining obstacles. Liver Int. 2014;34(5):668-71. 
https://doi.org/10.1111/liv.12467.
21. Shah HA, Abu-Amara M. Education provides significant benefits to patients with hepatitis 
B virus or hepatitis C virus infection: a systematic review. Clin Gastroenterol Hepatol. 
2013;118):922-33. https://doi.org/10.1016/j.cgh.2013.04.024.
22. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations 
for the identification of chronic hepatitis C virus infection among persons born during 
1945-1965. MMWR Recomm Rep. 2012;61(RR-4);1-18.
23. Sundus A, Siddique O, Ibrahim MF, Abbasi Z, Aziz S. Hepatitis patients lost to follow-up at a 
liver centre in a tertiary care hospital of Karachi, Pakistan – a cross-sectional descriptive study. 
J Park Med Assoc. 2013;63(12):1566-70.
24. Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care 
and stigmatization from a social perspective. Clin Infect Dis. 2013;57 Suppl 2:S51-5. 
https://doi.org/10.1093/cid/cit263.
25. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. 
Semin Liver Dis. 2000;20(1):1-16.
26. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, et al. Strategies 
to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21 Suppl 1:60-89. 
https://doi.org/10.1111/jvh.12249.
27. Yehia BR, Scharanz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis 
C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 
2014;9(7):e101554. https://doi.org/10.1371/journal.pone.0101554.
28. Younossi ZM, Stepanova M, Afendy M, Lam BP, Mishra A. Knowledge about infection is the 
only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat. 2013;20(8):550-5. 
https://doi.org/10.1111/jvh.12080.
29. Zeremski M, Zibbel JE, Martinez AD, Kritz S, Smith BD, Talal AH. Hepatitis C virus control 
among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol. 
2013;19(44):7846-51. https://doi.org/10.3748/wjg.v19.i44.7846.
Funding: Produtos Roche Químicos e Farmacêuticos S.A., Brazil (Process 8583).
Authors’ Contribution: Designing and planning the study: CAN, JRRP, LC, AFC, FRMA, ACSSN, ECS, MCMC. 
Data collection: SMM, FMM, LC, AFC, FRMA, ACSSN, RAFS. Data analysis and interpretation: SMM, MCMC. 
Preparing and writing the unpublished study: SMM, CAN, JRRP, ECS, MCMC. Critical review: CAN, JRRP, ECS, 
MCMC. Final approval: SMM, CAN, JRRP, FMM, LC, AFC, FRMA, ACSSN, RAFS, ECS, MCMC.
Conflict of Interest: This study received financial support from a Brazilian pharmaceutical company (Produtos 
Roche Químicos Farmacêuticos S.A). However, it was not involved with the study design or with its results or 
final analyzes.
